Humacyte Stock Performance
| HUMAW Stock | USD 1.85 0.02 1.09% |
On a scale of 0 to 100, Humacyte holds a performance score of 3. The company retains a Market Volatility (i.e., Beta) of 1.56, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Humacyte will likely underperform. Please check Humacyte's semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Humacyte's current trending patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Humacyte are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Humacyte showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Renaissance Technologies LLC Purchases 524,600 Shares of Humacyte, Inc. - MarketBeat | 10/01/2024 |
2 | The Law Offices of Frank R. Cruz Continues Its Investigation of Humacyte, Inc. on Behalf of Investors - Business Wire | 11/06/2024 |
3 | HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - Morningstar | 11/20/2024 |
4 | SHAREHOLDER ALERT Pomerantz Law Firm Announces the Filing of a Class Action Against Humacyte, Inc.- HUMA - PR Newswire | 12/03/2024 |
5 | HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Marketscreener.com | 12/11/2024 |
6 | Humacyte Shares Surge 38 percent on FDA Approval of Symvess - MarketWatch | 12/20/2024 |
| Begin Period Cash Flow | 149.8 M | |
| Free Cash Flow | -75.6 M |
Humacyte |
Humacyte Relative Risk vs. Return Landscape
If you would invest 184.00 in Humacyte on September 27, 2024 and sell it today you would earn a total of 1.00 from holding Humacyte or generate 0.54% return on investment over 90 days. Humacyte is currently producing 0.3681% returns and takes up 8.7017% volatility of returns over 90 trading days. Put another way, 77% of traded stocks are less volatile than Humacyte, and 93% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Humacyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Humacyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Humacyte, and traders can use it to determine the average amount a Humacyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0423
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HUMAW | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.7 actual daily | 77 77% of assets are less volatile |
Expected Return
| 0.37 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Humacyte is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Humacyte by adding it to a well-diversified portfolio.
Humacyte Fundamentals Growth
Humacyte Stock prices reflect investors' perceptions of the future prospects and financial health of Humacyte, and Humacyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Humacyte Stock performance.
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 | ||||
| EBITDA | (96.46 M) | ||||
| Net Income | (110.78 M) | ||||
| Total Debt | 58.11 M | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (73.31 M) | ||||
| Earnings Per Share | (3.16) X | ||||
| Total Asset | 128.22 M | ||||
| Retained Earnings | (537.31 M) | ||||
| Working Capital | 64.83 M | ||||
About Humacyte Performance
Evaluating Humacyte's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Humacyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Humacyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (1.58) | (1.50) | |
| Return On Tangible Assets | (0.86) | (0.82) | |
| Return On Capital Employed | (0.91) | (0.96) | |
| Return On Assets | (0.86) | (0.82) | |
| Return On Equity | (8.18) | (7.77) |
Things to note about Humacyte performance evaluation
Checking the ongoing alerts about Humacyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Humacyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Humacyte had very high historical volatility over the last 90 days | |
| Humacyte may become a speculative penny stock | |
| Humacyte has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (110.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Humacyte generates negative cash flow from operations | |
| Latest headline from news.google.com: Humacyte Shares Surge 38 percent on FDA Approval of Symvess - MarketWatch |
- Analyzing Humacyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Humacyte's stock is overvalued or undervalued compared to its peers.
- Examining Humacyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Humacyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Humacyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Humacyte's stock. These opinions can provide insight into Humacyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.